Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
Pharnext SA — the French biopharmaceutical company developing PXT3003 as a therapeutic candidate to treat Charcot-Marie-Tooth disease type 1A (CMT1A) — announced that it has successfully raised 16 million euros, ... Read more
Researchers have found that two proteins, Sox2 and Id2, play a protective role in preventing further damage in specialized nervous system cells of a mouse model of Charcot-Marie-Tooth disease ... Read more
ACE-083, an investigative therapy for the treatment of Charcot-Marie-Tooth (CMT) disease, was well tolerated and resulted in increased targeted muscle growth in healthy volunteers in a Phase 1 clinical ... Read more
The proteins NME3 and CSNK1G3 can help increase production of proteins lacking in genetic diseases with an underlying nonsense mutation – such as Charcot-Marie-Tooth type 2 disease – leading ... Read more
Researchers have found that low levels of ceramide, a lipid molecule, leads to changes in mitochondrial structure and function, resulting in the neuronal degeneration seen in CMT2F, a form ... Read more
A lot of people with Charcot-Marie-Tooth (CMT) disease have surgery to correct foot deformities, a British study reports. Another important finding was that an operation requires a number of ... Read more
Researchers have identified MCM3AP as a gene involved in the development of a childhood-onset version of the neurological disorder Charcot-Marie-Tooth disease. The study, “MCM3AP in recessive Charcot-Marie-Tooth neuropathy and mild intellectual ... Read more